Absorption and subcellular localization of lycopene in human prostate cancer cells.

Absorption and subcellular localization of lycopene in human prostate cancer cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Absorption and subcellular localization of lycopene in human prostate cancer cells. Abstract Text:

Ang Liu,Natasa Pajkovic,Yan Pang,Dongwei Zhu,Barbara Calamini,Andrew L Mesecar,Richard B van Breemen,

Lycopene, the red pigment of the tomato, is under investigation for the chemoprevention of prostate cancer. Because dietary lycopene has been reported to concentrate in the human prostate, its uptake and subcellular localization were investigated in the controlled environment of cell culture using the human prostate cancer cell lines LNCaP, PC-3, and DU145. After 24 hours of incubation with 1.48 micromol/L lycopene, LNCaP cells accumulated 126.6 pmol lycopene/million cells, which was 2.5 times higher than PC-3 cells and 4.5 times higher than DU145 cells. Among these cell lines, only LNCaP cells express prostate-specific antigen and fully functional androgen receptor. Levels of prostate-specific antigen secreted into the incubation medium by LNCaP cells were reduced 55% as a result of lycopene treatment at 1.48 micromol/L. The binding of lycopene to the ligand-binding domain of the human androgen receptor was carried out, but lycopene was not found to be a ligand for this receptor. Next, subcellular fractionation of LNCaP cells exposed to lycopene was carried out using centrifugation and followed by liquid chromatography-tandem mass spectrometry quantitative analysis to determine the specific cellular locations of lycopene. The majority of lycopene (55%) was localized to the nuclear membranes, followed by 26% in nuclear matrix, and then 19% in microsomes. No lycopene was detected in the cytosol. These data suggest that the rapid uptake of lycopene by LNCaP cells might be facilitated by a receptor or binding protein and that lycopene is stored selectively in the nucleus of LNCaP cells.

Absorption and subcellular localization of lycopene in human prostate cancer cells. Publishing Authors By Initials

A Liu,N Pajkovic,Y Pang,D Zhu,B Calamini,AL Mesecar,RB van Breemen,

For similar cells: cells, cultured: tumor cells, cultured research abstracts see: cells: cells, cultured: tumor cells, cultured research

PUBMED ID PMID:

MEDLINE DATE:

Absorption and subcellular localization of lycopene in human prostate cancer cells. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Molecular cancer therapeutics

VOLUME: 5

Page Numbers: 2879-85

Journal Abbreviation: Mol. Cancer Ther.

ISSN: 1535-7163

DAY: 3

MONTH: Nov

YEAR: 2006

Absorption and subcellular localization of lycopene in human prostate cancer cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101132535

Absorption and subcellular localization of lycopene in human prostate cancer cells. Keywords Mesh Terms:

KEYWORDS: Tumor Cells, Cultured

MESH TERMS: metabolism

Chemical & Substance for Abstract: Absorption and subcellular localization of lycopene in human prostate cancer cells. Information

Substance Name: lycopene

Registry Number: 502-65-8

Grant and Affiliation Information for Absorption and subcellular localization of lycopene in human prostate cancer cells.

AFFILIATION: Department of Medicinal Chemistry and Pharmacognosy, University of Illinois College of Pharmacy, 833 South Wood Street, M/C 781, Chicago, IL 60612-7231. Breemen@uic.edu.

Country: United States

AGENCY: United States NCI

GRANT: R01 CA101052

ACRONYM: CA

MEDLINETA: Mol Cancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Absorption and subcellular localization of lycopene in human prostate cancer cells Related Publications

• Absorption and subcellular localization of lycopene in human prostate cancer cells.
• An improved LC-MS/MS method for the quantification of prostaglandins E(2) and D(2) production in biological fluids.
• Binding of the hop (Humulus lupulus L.) chalcone xanthohumol to cytosolic proteins in Caco-2 intestinal epithelial cells.
• Biotransformation of the chemopreventive agent 2',4',4-trihydroxychalcone (isoliquiritigenin) by UDP-glucuronosyltransferases.
• Ca2+ signaling in smooth muscle: TRPC6, NCX and LNats in nanodomains.
• Development of a Screening Assay for Ligands to the Estrogen Receptor Based on Magnetic Microparticles and LC-MS.
• Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome.
• Estrogen effects on the vascular wall.
• Imbalanced synthesis of cyclooxygenase-derived thromboxane A2 and prostacyclin compromises vasomotor function of the thoracic aorta in Marfan syndrome.
• In vitro metabolism of isoliquiritigenin by human liver microsomes.
• Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction.
• Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9.
• Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome.
• Quantitative analyses of beta-carotene and retinol in serum and feces in support of clinical bioavailability studies.
• Sites of alkylation of human Keap1 by natural chemoprevention agents.
• Transient receptor potential channel 6-mediated, localized cytosolic [Na+] transients drive Na+/Ca2+ exchanger-mediated Ca2+ entry in purinergically stimulated aorta smooth muscle cells.
• [In Process Citation]